Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
about
Receptor-binding domain-based subunit vaccines against MERS-CoVCurrent advancements and potential strategies in the development of MERS-CoV vaccinesThe adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primatesYeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate.Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin.A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityThe epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.An eight-year epidemiologic study based on baculovirus-expressed type-specific spike proteins for the differentiation of type I and II feline coronavirus infections.A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccinesProtocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndromeReceptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines.Middle East respiratory syndrome vaccines.A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoVAnimal models in virus research: their utility and limitations.Vaccines for the prevention against the threat of MERS-CoV.Identification and characterization of a neutralizing-epitope-containing spike protein fragment in turkey coronavirus.A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV
P2860
Q26851979-F17002C4-CE64-412C-AA3B-DE3760A85A33Q27012578-B0F56C9F-EDA7-4C86-B28F-E235C83E36C3Q28729899-A4E9DB8D-4900-48FB-810A-C24BE7969F2DQ30218075-DCBAFBDD-2C00-469F-9C7B-DED0B07D17B6Q30359335-7B1B4867-70AA-488B-A296-93E5A4A7113FQ30371303-ED083FB0-2723-4BE9-B985-496CC4B8618CQ30378994-5198F262-D1CD-4CE1-AB0C-68A075BA6370Q30401512-BF952B42-BFA5-44E2-8687-6138B37186B8Q30432706-6369C1CD-1D38-4794-8D84-21260A2BA841Q30535722-7BC6CFB8-5097-4D3E-A1CA-04747D524FF0Q33743790-E42D7A99-9F6E-44C5-BCB1-7177BD028ADAQ33815195-3D4C244B-3DED-4647-8624-F88561AA2C68Q33904997-8B732FCF-E13B-4392-9957-5C12D8F090A7Q34291530-E5BFED87-63D8-459F-93F8-5DCC5653045FQ34324907-4CA0421E-200E-43A5-BF5D-5DA29CF7FC18Q34332142-000F786A-B6FA-496D-80BC-0D2315375D15Q34539529-9F338990-0E5B-40FD-96B7-6CF3B772A7A3Q35063993-8EF04AF9-5466-41BE-A385-807BDBC640DDQ35392075-636201B8-148A-490A-B2AB-7FAE86E571F1Q36650501-B5ED5928-91AB-4021-8623-918E4C5893C6Q36779713-8D4C235B-B665-41EA-BEAC-C479B7755B33Q37143501-52360E33-6163-4AFD-86A7-C69BE86ED449Q37152873-9A068743-2607-4ED4-9908-C267171D8844Q38043556-D2906588-DB0E-4FAF-BF04-3A9C02F1BB43Q38778044-30C9CCE1-C33D-48BC-A5E4-0C0986B3939DQ43753428-EBF34924-0C40-4B0A-9559-F1A3207F2294Q58710181-172476E4-B394-4607-85E1-D1E7A6D42E3A
P2860
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recombinant receptor-binding d ...... ibody and protective immunity.
@en
Recombinant receptor-binding d ...... ibody and protective immunity.
@nl
type
label
Recombinant receptor-binding d ...... ibody and protective immunity.
@en
Recombinant receptor-binding d ...... ibody and protective immunity.
@nl
prefLabel
Recombinant receptor-binding d ...... ibody and protective immunity.
@en
Recombinant receptor-binding d ...... ibody and protective immunity.
@nl
P2093
P2860
P921
P1433
P1476
Recombinant receptor-binding d ...... ibody and protective immunity.
@en
P2093
Bo-Jian Zheng
Chris C S Chan
Guangyu Zhao
Hongxiang Guo
Shihui Sun
Yusen Zhou
Zhonghua Liu
P2860
P304
P356
10.1016/J.VIROL.2009.07.018
P407
P577
2009-08-15T00:00:00Z